Rifampin (RMP), a first-line antituberculosis drug, reaches serum concentrations well below suggested lower limits when a standard dose of 8-12mg/kg body weight is given to children. A pharmacokinetic study, published in the open access journal BMC Medicine, suggests that a higher dose of 10-20mg/kg may be more appropriate.
H. Simon Schaaf from the University of Stellenbosch, South Africa, led a team of researchers who studied 54 children admitted to hospital with severe tuberculosis, 21 of whom also had HIV infection. He said, "The mean calculated 2h RMP concentrations in these HIV-infected and HIV-uninfected children were 3.9 and 4.8μg/ml, respectively, at 1-month after treatment start and 4.0 and 4.6μg/ml after 4-months treatment. These values are considerably less than the suggested lower limit for 2h RMP concentrations in adults of 8.0μg/ml".
Although there is some evidence that the low concentrations achieved may be effective in treating tuberculosis, Schaaf and his colleagues sound a note of caution regarding the more severe forms of tuberculosis such as are increasingly encountered in the developing world, especially in association with HIV infection. They write, "In the era of HIV/AIDS, any reduction in the dose of antituberculosis agents reflected by frequency and length of treatment, particularly in more severe forms of pulmonary tuberculosis, may be associated with an increased risk of relapse".
The dosage of RMP recommended for use in children in the United States of America is 15mg/kg with a range of 10-20mg/kg body weight. The authors conclude that this should be the standard globally, "We believe that the recommended RMP dose of 10-20 mg/kg for children by the American Academy of Pediatrics is a more appropriate dosage range".
Notes to Editors
1. Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis
Hendrik Simon Schaaf, Marianne Willemse, Karien Cilliers, Demetre Labadarios, Johannes Stephanus Maritz, Gregory D Hussey, Helen McIlleron, Peter Smith and Peter Roderick Donald
BMC Medicine (in press)
During embargo, article available here: http://www.
After the embargo, article available at the journal website: http://www.
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at email@example.com on the day of publication.
2. BMC Medicine - the flagship medical journal of the BMC series - publishes original research articles, commentaries and reviews in all areas of medical science and clinical practice. To be appropriate for BMC Medicine, articles need to be of outstanding quality, broad interest and special importance. BMC Medicine (ISSN 1741-7015) is indexed/tracked/covered by PubMed, MEDLINE, BIOSIS, CAS, Scopus, EMBASE, Current Contents, Thomson Reuters (ISI) and Google Scholar.
3. BioMed Central (http://www.